Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

New study confirms the effectiveness of LDCT screening in a never-smoker high-risk population

A study presented today by researchers with the Ministry of Health and Welfare in Taiwan confirmed the effectiveness of low-dose computed tomography (LDCT) screening in a pre-defined, never-smoker, high-risk population.

31 Jan 2021

Researchers examine the connection between lung cancer and COVID-19

On February 27, 2020, the flagship journal of the International Association for the Study of Lung Cancer, the Journal of Thoracic Oncology, published a case study that described two patients from Wuhan, China who recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery.

30 Jan 2021

Researchers develop an easier way to deliver pancreatic cancer drugs

Researchers with the Kansas City Veterans Affairs Medical Center and North Dakota State University have designed a new way to deliver pancreatic cancer drugs that could make fighting the disease much easier.

29 Jan 2021

Researchers identify protein that may represent a safer treatment target for pancreatic cancer

Researchers from Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer.

22 Jan 2021

Dynamic, customized treatment approaches for gastroesophageal cancers may improve survival rates

A phase 2 clinical trial providing personalized treatments based on the genetic profile of metastatic tumors in gastroesophageal cancers has found that using customized treatment approaches, and adapting them over time as tumors become resistant, led to higher rates of survival compared to historical controls.

21 Jan 2021

SARS-CoV-2-induced innate immune responses may vary with disease severity, finds study

Scientists from Germany and China recently conducted a large meta-analysis using transcriptome data of SARS-CoV-2 to evaluate the routes of viral entry and the characteristics of innate immune responses induced by SARS-CoV-2 infection.

11 Jan 2021

No added risks to radiation therapy for cancer patients with COVID-19, says study

A team of radiation oncologists at the Zucker School of Medicine at Hofstra/Northwell in the United States aimed to determine if COVID-19 infected cancer patients receiving radiation therapy (RT) have any different outcome than non-infected patients.

17 Dec 2020

Study shows rising incidence of esophageal adenocarcinoma in younger adults

Esophageal adenocarcinoma is occurring more frequently in adults under age 50, and these younger adults are more likely to be diagnosed at advanced stages.

16 Dec 2020

Imaging, morphologic metrics associated with pathologic response in pancreatic cancer patients

According to an open-access Editor's Choice article in ARRS' American Journal of Roentgenology (AJR), post-neoadjuvant therapy (NAT) changes in metabolic metrics from PET/MRI and morphologic metrics from CT were associated with pathologic response and overall survival in patients with pancreatic ductal adenocarcinoma (PDA).

9 Dec 2020

Surprising discovery reveals new target for aggressive lung adenocarcinoma

Targeted therapies are currently available for about one-third of people with lung adenocarcinoma, the most common kind of lung cancer.

2 Dec 2020

Are SARS-CoV-2 protease inhibitors effective antivirals in treating COVID-19?

Many antiviral development studies have focused on the possibility of inhibiting the main viral protease (Mpro), and papain-like protease (PLpro), given their central role in viral replication. A new study draws attention to the high odds that these may not have anti-infective activity because of the redundant pathways present in human host cells.

30 Nov 2020

PARP inhibitor, stenoparib inhibits pre- and post-entry processes of SARS-CoV-2 in vitro

A team of researchers from the Northern Arizona University evaluated a new PARP inhibitor, stenoparib, which has recently advanced to Stage II of clinical trials to treat ovarian cancer. Their study, an initial report on in vitro stenoparib activity against human coronaviruses such as SARS-CoV-2, has been published on the preprint server bioRxiv*.

15 Nov 2020

JNCCN: Cost-effectiveness of olaparib for metastatic pancreatic cancer

Studies have shown that utilizing a PARP inhibitor in the management of patients with metastatic pancreatic cancer who harbor BRCA 1/2 mutations is clinically beneficial.

12 Nov 2020

Remdesivir metabolite GS-441524 inhibits SARS CoV-2 in mouse model, finds study

This new study titled, "Remdesivir Metabolite GS-441524 Efficiently Inhibits SARS-CoV-2 Infection in Mouse Model," was released online as a preprint on the bioRxiv* server, prior to undergoing the peer-review process.

2 Nov 2020

Time machine suggests a drug testing approach for pancreatic cancer

Many patients with pancreatic cancer have only about a 10% chance of survival within five years of their diagnosis because they tend to become resistant to chemotherapy, past studies have indicated.

30 Oct 2020

Researchers use single-cell sequencing to identify cell types that occur in pancreatic tumors

Led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and by HonorHealth Research and Innovation Institute, an international team of researchers have described in detail the individual cells that comprise the pancreatic cancer microenvironment, a critical step in devising new treatment options for patients with this aggressive and difficult-to-treat disease.

1 Oct 2020

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival.

21 Sep 2020

Post-operative radiotherapy in NSCLC shows no statistically difference in 3-year disease-free survival

Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and after (neo) adjuvant chemotherapy shows no statistically significant difference in 3-year disease-free survival (DFS), according to data presented at ESMO 2020.

21 Sep 2020

Researchers identify specific potential therapeutic targets for aggressive form of pancreatic cancer

A team of researchers led by Mayo Clinic and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has identified specific potential therapeutic targets for the most aggressive and lethal form of pancreatic cancer.

15 Sep 2020

Six genomics research projects receive grants to address the role of ethnicity in major cancers

Leading cancer scientists working with the New York Genome Center (NYGC) announced today that grants are being awarded to fund six projects that address the role of ethnicity in several major cancer types, taking advantage of the diversity of patients being treated at health care institutions throughout the New York City area.

8 Sep 2020